Zelboraf 240mg

Zelboraf (Vemurafenib) is a kinase inhibitor used for the treatment of patients with:

• unresectable or metastatic melanoma with BRAF V600E mutation. 
• Erdheim-Chester Disease with BRAF V600 mutation.

• Dermatologic evaluations should be performed prior to initiation of zelboraf 240 mg therapy and every 2 months while on therapy. 
• Vemurafenib therapy may promote malignancies linked with activation of RAS through mutation or other mechanisms. Monitor patients receiving vemurafenib dose closely for symptoms of other malignancies.
• Non-cutaneous squamous cell carcinomas (non-cuSCC) of the head and neck can occur in patients with vemurafenib 240 mg. Monitor patients receiving vemurafenib closely for signs of new non-cuSCC.
• Monitor patients for transaminases, alkaline phosphatase, and bilirubin prior to the initiation of therapy with vemurafenib tablets and monthly while on therapy.
• Vemurafenib can cause fetal harm if administered to a pregnant woman. Females of reproductive potential should use effective contraception during treatment with zelboraf tablets and for 2 weeks after the final dose. 
• Monitor patients closely when therapy with vemurafenib is administered concomitantly or sequentially with radiation treatment.
• Patients should be measured for the serum creatinine before initiation of zelboraf dosage and periodically while on treatment.

What documents are required to import ZELBORAF to India?

ZELBORAF Tablets (Vemurafenib) can be imported by patients or government hospitals on the name of the patients only. 

The following documentation required to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients id proof (issued by government of India)

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
• Import permit if applicable

Is ZELBORAF available in India?

ZELBORAF is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input

• On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
• Medicine Price.
• Finding Genuine and reliable source from Canada, Europe, USA and Australia
• Ensuring 100% transparency.

ZELBORAF can be made available in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune and other cities in India. 

Indian Pharma Network can facilitate the supply of ZELBORAF (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable). 

Please contact +91 9310090915- Toll Free  – 1800- 889- 1064 for zelboraf 240 mg price in India. 

We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

What is the Generic Name for the trade name drug Zelboraf® ?

Vemurafenib is Generic Name for the trade name drug Zelboraf®.

What is the Manufacturer Name of Zelboraf®?

Zelboraf® is manufactured by Roche. 

Is Zelboraf® approved by the FDA?

Yes, Zelboraf® is approved by the FDA. Date of approval August 17, 2011.

What is the dosage and form of Zelboraf® available?

Zelboraf® is available as Tablets of 240 mg for oral administration. 

What are the most common side effects of Zelboraf® in melanoma? 

The most commonly reported zelboraf side effects in melanoma include Joint pain, Rash, Hair loss, Sunburn or sun sensitivity, Nausea, Itching and Warts. 

What are the most common side effects of Vemurafenib in Erdheim-Chester Disease?

The most commonly reported vemurafenib side effects in Erdheim-Chester Disease include Joint pain, Tiredness, Hair loss and QT prolongation. 

What are the Highlights of prescribing information for Zelboraf®?

Click Here to download full zelboraf prescribing information.